Exposure to estrogen is associated with increased risk of breast and other types of human cancer. One therapeutic goal would be the creation of new molecules that would retain hormonal potency while incorporating features to retard or prevent quinone toxicity. Hence, new structures closely related to ERB-041, a known ERβ selective agonist, were synthesized whereas the phenol ring is substituted with non-quinone forming rings such as pyrazole, 2-pyrimidine-2(1H)-one or pyridine-2(1H)-one. 2-Methyl-5-methoxy-1,3-benzoxazoles (or 1,3-benzothiazole) are key intermediates for the production of the pyrazole and pyrimidine-2(1H)-one analogs. The required 1,3-benzoxazoles were synthesized starting from reduction of 2-nitro-4-methoxyphenols, followed by condensation with trimethyl orthoacetate. Then, the diiminium perchlorate intermediates were prepared from the latter compounds by Vilsmeier–Haack reaction. The reaction of the resulting intermediates with hydrazine hydrate and guanidium chloride afforded the title pyrazole and pyrimidine-2(1H)-ones, respectively.

The pyridine analogs were synthesized starting from the reaction of 2-amino-4-methoxyphenols with 6-bromopyridine-3-carboxaldehyde followed by oxidation with DDQ to afford bromopyridines. These compounds were next treated with benzyl alcohol in the presence of potassium tert-butoxide to afford 2-benzyloxypyridine, which in subsequent dealkylation with boron tribromide produced the title pyridine-2-(1H)-ones.

暴露于雌激素会增加乳腺癌和其他类型人类癌症的风险。一个治疗目标将是创造一种新的分子，该分子在保留能抑制或预防醌毒性的功能的同时，保持激素的效力。因此，合成了与ERB-041（一种已知的ERβ选择性激动剂）密切相关的新结构，而苯酚环被形成非醌的环如吡唑，2-嘧啶-2（1 H）-one或吡啶-2取代。（1 H）-一。2-甲基-5-甲氧基-1,3-苯并恶唑（或1,3-苯并噻唑）是生产吡唑和嘧啶-2（1 H）-一个类似物。从还原2-硝基-4-甲氧基苯酚开始，然后与原乙酸三甲酯缩合，合成了所需的1,3-苯并恶唑。然后，通过Vilsmeier-Haack反应从后一种化合物制备高氯酸二亚胺中间体。所得中间体与水合肼和氯化胍的反应分别得到标题吡唑和嘧啶-2（1H）-一。

吡啶类似物的合成从2-氨基-4-甲氧基苯酚与6-溴吡啶-3-甲醛的反应开始，然后用DDQ氧化得到溴吡啶。然后在叔丁醇钾存在下用苄醇处理这些化合物，得到2-苄氧基吡啶，其随后用三溴化硼脱烷基，得到标题吡啶-2-（1H）-一。